Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Gyre Therapeutics (GYRE) over the last 15 years, with Q3 2025 value amounting to $228000.0.

  • Gyre Therapeutics' Other Accumulated Expenses fell 8229.81% to $228000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $228000.0, marking a year-over-year decrease of 8229.81%. This contributed to the annual value of $227000.0 for FY2024, which is 8341.86% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Other Accumulated Expenses of $228000.0 as of Q3 2025, which was down 8229.81% from $219000.0 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Other Accumulated Expenses ranged from a high of $8.1 million in Q3 2021 and a low of $118000.0 during Q4 2022
  • In the last 5 years, Gyre Therapeutics' Other Accumulated Expenses had a median value of $1.3 million in 2024 and averaged $2.2 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first crashed by 9776.52% in 2022, then soared by 106016.95% in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Other Accumulated Expenses stood at $4.1 million in 2021, then tumbled by 97.1% to $118000.0 in 2022, then skyrocketed by 1060.17% to $1.4 million in 2023, then crashed by 83.42% to $227000.0 in 2024, then rose by 0.44% to $228000.0 in 2025.
  • Its Other Accumulated Expenses was $228000.0 in Q3 2025, compared to $219000.0 in Q2 2025 and $228000.0 in Q1 2025.